Taysha Gene Therapies gears up to approach regulators with a new candidate for a debilitating neurodegenerative disease

Nicole DeFeudis

Editor

After launching early last year, Taysha Gene Therapies quickly went about checking off key milestones. Within five months, it pulled in a hefty Series B …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Taysha Gene Therapies gears up to approach regulators with a new candidate for a debilitating neurodegenerative disease

Nicole DeFeudis

Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Taysha Gene Ther­a­pies gears up to ap­proach reg­u­la­tors with a new can­di­date for a de­bil­i­tat­ing neu­rode­gen­er­a­tive dis­ease

Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Taysha Gene Therapies gears up to approach regulators with a new candidate for a debilitating neurodegenerative disease